JP2020530981A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020530981A5 JP2020530981A5 JP2019572710A JP2019572710A JP2020530981A5 JP 2020530981 A5 JP2020530981 A5 JP 2020530981A5 JP 2019572710 A JP2019572710 A JP 2019572710A JP 2019572710 A JP2019572710 A JP 2019572710A JP 2020530981 A5 JP2020530981 A5 JP 2020530981A5
- Authority
- JP
- Japan
- Prior art keywords
- antisense oligonucleotide
- exon
- cell
- target region
- optionally
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108091034117 Oligonucleotide Proteins 0.000 claims description 83
- 239000000074 antisense oligonucleotide Substances 0.000 claims description 69
- 238000012230 antisense oligonucleotides Methods 0.000 claims description 69
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 36
- 238000000034 method Methods 0.000 claims description 21
- 108090000623 proteins and genes Proteins 0.000 claims description 21
- 108020004707 nucleic acids Proteins 0.000 claims description 14
- 102000039446 nucleic acids Human genes 0.000 claims description 14
- 150000007523 nucleic acids Chemical class 0.000 claims description 12
- 239000000203 mixture Substances 0.000 claims description 11
- 108020004414 DNA Proteins 0.000 claims description 10
- 210000004027 cell Anatomy 0.000 claims description 10
- 229920002477 rna polymer Polymers 0.000 claims description 10
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 claims description 10
- 206010028980 Neoplasm Diseases 0.000 claims description 8
- 201000011510 cancer Diseases 0.000 claims description 8
- 230000004957 immunoregulator effect Effects 0.000 claims description 8
- 108091033319 polynucleotide Proteins 0.000 claims description 8
- 102000040430 polynucleotide Human genes 0.000 claims description 8
- 239000002157 polynucleotide Substances 0.000 claims description 8
- 108700042075 T-Cell Receptor Genes Proteins 0.000 claims description 7
- -1 2- Methoxyethyl phosphodiester Chemical class 0.000 claims description 6
- 229940059260 amidate Drugs 0.000 claims description 6
- 108700024394 Exon Proteins 0.000 claims description 5
- 201000010099 disease Diseases 0.000 claims description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 5
- 238000004520 electroporation Methods 0.000 claims description 5
- 108020004999 messenger RNA Proteins 0.000 claims description 5
- 230000001105 regulatory effect Effects 0.000 claims description 5
- 102000001398 Granzyme Human genes 0.000 claims description 4
- 108060005986 Granzyme Proteins 0.000 claims description 4
- 102100037850 Interferon gamma Human genes 0.000 claims description 4
- 108010074328 Interferon-gamma Proteins 0.000 claims description 4
- 102000004503 Perforin Human genes 0.000 claims description 4
- 108010056995 Perforin Proteins 0.000 claims description 4
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims description 4
- 239000002253 acid Substances 0.000 claims description 4
- 238000012986 modification Methods 0.000 claims description 4
- 230000004048 modification Effects 0.000 claims description 4
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 4
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 claims description 3
- 102100035990 Adenosine receptor A2a Human genes 0.000 claims description 3
- 208000023275 Autoimmune disease Diseases 0.000 claims description 3
- 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 claims description 3
- 101710083479 Hepatitis A virus cellular receptor 2 homolog Proteins 0.000 claims description 3
- 101000783751 Homo sapiens Adenosine receptor A2a Proteins 0.000 claims description 3
- 101001137987 Homo sapiens Lymphocyte activation gene 3 protein Proteins 0.000 claims description 3
- 102000017578 LAG3 Human genes 0.000 claims description 3
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims description 3
- 108010029485 Protein Isoforms Proteins 0.000 claims description 3
- 102000001708 Protein Isoforms Human genes 0.000 claims description 3
- 229940126547 T-cell immunoglobulin mucin-3 Drugs 0.000 claims description 3
- 230000000840 anti-viral effect Effects 0.000 claims description 3
- 229910000389 calcium phosphate Inorganic materials 0.000 claims description 3
- 239000001506 calcium phosphate Substances 0.000 claims description 3
- 235000011010 calcium phosphates Nutrition 0.000 claims description 3
- 230000000694 effects Effects 0.000 claims description 3
- 150000002632 lipids Chemical class 0.000 claims description 3
- 230000001404 mediated effect Effects 0.000 claims description 3
- 239000002773 nucleotide Substances 0.000 claims description 3
- 230000003204 osmotic effect Effects 0.000 claims description 3
- 150000003013 phosphoric acid derivatives Chemical class 0.000 claims description 3
- 238000001556 precipitation Methods 0.000 claims description 3
- 230000035939 shock Effects 0.000 claims description 3
- 238000011282 treatment Methods 0.000 claims description 3
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 claims description 3
- 102100023990 60S ribosomal protein L17 Human genes 0.000 claims description 2
- 108020000948 Antisense Oligonucleotides Proteins 0.000 claims description 2
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 claims description 2
- 108090000695 Cytokines Proteins 0.000 claims description 2
- 102000004127 Cytokines Human genes 0.000 claims description 2
- 102000053602 DNA Human genes 0.000 claims description 2
- 239000004677 Nylon Substances 0.000 claims description 2
- 108091093037 Peptide nucleic acid Proteins 0.000 claims description 2
- KHGNFPUMBJSZSM-UHFFFAOYSA-N Perforine Natural products COC1=C2CCC(O)C(CCC(C)(C)O)(OC)C2=NC2=C1C=CO2 KHGNFPUMBJSZSM-UHFFFAOYSA-N 0.000 claims description 2
- ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical group OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 claims description 2
- RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical group OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 claims description 2
- 239000002246 antineoplastic agent Substances 0.000 claims description 2
- 239000000412 dendrimer Substances 0.000 claims description 2
- 229920000736 dendritic polymer Polymers 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 210000005260 human cell Anatomy 0.000 claims description 2
- 230000001939 inductive effect Effects 0.000 claims description 2
- 238000002372 labelling Methods 0.000 claims description 2
- 229920001778 nylon Polymers 0.000 claims description 2
- 229940124276 oligodeoxyribonucleotide Drugs 0.000 claims description 2
- 125000004430 oxygen atom Chemical group O* 0.000 claims description 2
- 229930192851 perforin Natural products 0.000 claims description 2
- 150000004713 phosphodiesters Chemical group 0.000 claims description 2
- 150000008298 phosphoramidates Chemical class 0.000 claims description 2
- 125000004434 sulfur atom Chemical group 0.000 claims description 2
- 208000036142 Viral infection Diseases 0.000 claims 2
- 230000009385 viral infection Effects 0.000 claims 2
- 238000000137 annealing Methods 0.000 claims 1
- 230000000259 anti-tumor effect Effects 0.000 claims 1
- 238000011394 anticancer treatment Methods 0.000 claims 1
- 231100000433 cytotoxic Toxicity 0.000 claims 1
- 230000001472 cytotoxic effect Effects 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 230000002519 immonomodulatory effect Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000012528 membrane Substances 0.000 claims 1
- 230000035755 proliferation Effects 0.000 claims 1
- 239000002502 liposome Substances 0.000 description 6
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 5
- 239000002105 nanoparticle Substances 0.000 description 4
- 229920000642 polymer Polymers 0.000 description 4
- 229920002307 Dextran Polymers 0.000 description 2
- 108091008036 Immune checkpoint proteins Proteins 0.000 description 2
- 102000037982 Immune checkpoint proteins Human genes 0.000 description 2
- 108091026823 U7 small nuclear RNA Proteins 0.000 description 2
- 125000002091 cationic group Chemical group 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 229940126546 immune checkpoint molecule Drugs 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- 239000013603 viral vector Substances 0.000 description 2
- 102100029822 B- and T-lymphocyte attenuator Human genes 0.000 description 1
- 108010074708 B7-H1 Antigen Proteins 0.000 description 1
- 102100024263 CD160 antigen Human genes 0.000 description 1
- 102100032937 CD40 ligand Human genes 0.000 description 1
- 101150091887 Ctla4 gene Proteins 0.000 description 1
- 101000864344 Homo sapiens B- and T-lymphocyte attenuator Proteins 0.000 description 1
- 101000761938 Homo sapiens CD160 antigen Proteins 0.000 description 1
- 101000868215 Homo sapiens CD40 ligand Proteins 0.000 description 1
- 101000973157 Homo sapiens NEDD4 family-interacting protein 1 Proteins 0.000 description 1
- 101000884270 Homo sapiens Natural killer cell receptor 2B4 Proteins 0.000 description 1
- 101001117312 Homo sapiens Programmed cell death 1 ligand 2 Proteins 0.000 description 1
- 101000831007 Homo sapiens T-cell immunoreceptor with Ig and ITIM domains Proteins 0.000 description 1
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 description 1
- 108091027974 Mature messenger RNA Proteins 0.000 description 1
- 102100022547 NEDD4 family-interacting protein 1 Human genes 0.000 description 1
- 102100038082 Natural killer cell receptor 2B4 Human genes 0.000 description 1
- 102100024894 PR domain zinc finger protein 1 Human genes 0.000 description 1
- 108010009975 Positive Regulatory Domain I-Binding Factor 1 Proteins 0.000 description 1
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 description 1
- 102100024213 Programmed cell death 1 ligand 2 Human genes 0.000 description 1
- 230000006052 T cell proliferation Effects 0.000 description 1
- 102100024834 T-cell immunoreceptor with Ig and ITIM domains Human genes 0.000 description 1
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000022534 cell killing Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 229940124447 delivery agent Drugs 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SG10201705285S | 2017-06-27 | ||
| SG10201705285SA SG10201705285SA (en) | 2017-06-27 | 2017-06-27 | Antisense oligonucleotides |
| PCT/SG2018/050313 WO2019004939A1 (en) | 2017-06-27 | 2018-06-27 | ANTISENSE OLIGONUCLEOTIDES FOR MODULATING THE FUNCTION OF A LYMPHOCYTE T |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020530981A JP2020530981A (ja) | 2020-11-05 |
| JP2020530981A5 true JP2020530981A5 (https=) | 2021-07-29 |
| JP7284718B2 JP7284718B2 (ja) | 2023-05-31 |
Family
ID=64742433
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019572710A Active JP7284718B2 (ja) | 2017-06-27 | 2018-06-27 | Ｔ細胞の機能を調節するためのアンチセンスオリゴヌクレオチド |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US12188016B2 (https=) |
| EP (1) | EP3645724A4 (https=) |
| JP (1) | JP7284718B2 (https=) |
| KR (1) | KR20200035937A (https=) |
| CN (1) | CN111630167B (https=) |
| AU (1) | AU2018291556B2 (https=) |
| CA (1) | CA3066035A1 (https=) |
| SG (2) | SG10201705285SA (https=) |
| WO (1) | WO2019004939A1 (https=) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN118147079A (zh) * | 2016-03-31 | 2024-06-07 | 来恩生物医药私人有限公司 | 表达外源病毒特异性t细胞受体(tcr)的非活化t细胞 |
| EP3475424A1 (en) | 2016-06-22 | 2019-05-01 | ProQR Therapeutics II B.V. | Single-stranded rna-editing oligonucleotides |
| US10941402B2 (en) | 2016-09-01 | 2021-03-09 | Proqr Therapeutics Ii B.V. | Chemically modified single-stranded RNA-editing oligonucleotides |
| GB201808146D0 (en) | 2018-05-18 | 2018-07-11 | Proqr Therapeutics Ii Bv | Stereospecific Linkages in RNA Editing Oligonucleotides |
| US11312963B2 (en) * | 2018-10-18 | 2022-04-26 | Synerk Inc. | Compositions and methods for inhibiting TIGIT gene expression |
| US20220177894A1 (en) * | 2019-04-02 | 2022-06-09 | Proqr Therapeutics Ii B.V. | Antisense oligonucleotides for immunotherapy |
| CN109988842B (zh) * | 2019-04-19 | 2022-12-06 | 上海吉玛制药技术有限公司 | 一种寡核苷酸标记探针原位检测pdl1的试剂组与应用 |
| JP2022532998A (ja) * | 2019-04-26 | 2022-07-21 | ストーク セラピューティクス，インク． | 選択的イントロンのスプライシングを調節するための方法及び組成物 |
| CN110157705B (zh) * | 2019-05-16 | 2021-06-18 | 苏州安天圣施医药科技有限公司 | 在pdcd1基因表达的剪接水平抑制pd-1信号的反义寡核苷酸及其筛选方法与应用 |
| US20220380774A1 (en) * | 2019-05-20 | 2022-12-01 | Olix Pharmaceuticals, Inc. | Asymmetric sirna inhibiting expression of pd-1 |
| JP7337373B2 (ja) * | 2019-07-29 | 2023-09-04 | サイアス株式会社 | 抗原特異的ｔ細胞の製造方法 |
| AU2020405049A1 (en) * | 2019-12-17 | 2022-06-23 | The General Hospital Corporation | Engineered immune cells with reduced toxicity and uses thereof |
| WO2021173812A1 (en) * | 2020-02-28 | 2021-09-02 | Aligos Therapeutics, Inc. | Methods and compositions for targeting pd-l1 |
| US20230183708A1 (en) * | 2020-04-30 | 2023-06-15 | Secarna Pharmaceuticals Gmbh & Co. Kg | PD-1-specific antisense oligonucleotide and its use in therapy |
| US20230365964A1 (en) * | 2020-09-10 | 2023-11-16 | Inserm (Institut National De La Santè Et De La Recherch Médicale | Use of splice switching oligonucleotides for exon skipping-mediated knockdown of nf-kb components in b cells |
| CN116615207A (zh) * | 2020-10-20 | 2023-08-18 | 伊姆诺私人投资有限公司 | 经修饰的免疫细胞 |
| WO2022136140A1 (en) | 2020-12-22 | 2022-06-30 | F. Hoffmann-La Roche Ag | Oligonucleotides targeting xbp1 |
| CN115216474B (zh) * | 2021-04-15 | 2025-09-30 | 武汉大学 | 促进pd-l1外显子3跳跃的反义寡核苷酸及其应用 |
| EP4074835A1 (en) * | 2021-04-15 | 2022-10-19 | Deutsches Krebsforschungszentrum - Stiftung des öffentlichen Rechts / Universität Heidelberg | H-1 pv expressing rnai effectors |
| WO2023073709A1 (en) * | 2021-10-27 | 2023-05-04 | Hadasit Medical Research Services & Development Ltd. | Nucleic acid agents modulating pd-1 isoforms |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6566132B1 (en) | 2001-04-26 | 2003-05-20 | Isis Pharmaceuticals, Inc. | Antisense modulation of Interferon gamma receptor 1 expression |
| CA2628093A1 (en) | 2005-11-08 | 2007-05-18 | Avi Biopharma, Inc. | Antisense oligonucleotide analog compounds targeting proprocessed ctla-4 mrna |
| US8501704B2 (en) | 2005-11-08 | 2013-08-06 | Sarepta Therapeutics, Inc. | Immunosuppression compound and treatment method |
| DK2735568T3 (da) * | 2006-05-10 | 2017-11-13 | Sarepta Therapeutics Inc | Oligonukleotidanaloger med kationiske bindinger mellem underenheder |
| EP2295543A1 (en) * | 2009-09-11 | 2011-03-16 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Method for the preparation of an influenza virus |
| WO2011120101A1 (en) | 2010-04-01 | 2011-10-06 | The University Of Queensland | Small rna molecules and methods of use |
| EP2825665B1 (en) | 2012-03-14 | 2017-09-06 | Ruprecht-Karls-Universität Heidelberg | Epigenetic signatures as marker for cardiomyopathies and myocardial insufficiencies |
| US20150017136A1 (en) | 2013-07-15 | 2015-01-15 | Cellectis | Methods for engineering allogeneic and highly active t cell for immunotherapy |
| WO2014078749A1 (en) | 2012-11-15 | 2014-05-22 | The Regents Of The University Of California | Splice modulating oligonucleotides that inhibit cancer |
| WO2014090985A1 (en) | 2012-12-13 | 2014-06-19 | Universität Leipzig | T-cell modulation by exon skipping |
| CN103820454B (zh) | 2014-03-04 | 2016-03-30 | 上海金卫生物技术有限公司 | CRISPR-Cas9特异性敲除人PD1基因的方法以及用于特异性靶向PD1基因的sgRNA |
| CA2945335A1 (en) * | 2014-04-18 | 2015-10-22 | Editas Medicine, Inc. | Crispr-cas-related methods, compositions and components for cancer immunotherapy |
| WO2016138278A2 (en) * | 2015-02-27 | 2016-09-01 | Idera Pharmaceuticals, Inc. | Compositions for inhibiting checkpoint gene expression and uses thereof |
| KR20260048600A (ko) * | 2015-03-27 | 2026-04-10 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | 변형된 t 세포 및 이의 제조 및 사용 방법 |
| JP6949728B2 (ja) * | 2015-05-29 | 2021-10-13 | ジュノー セラピューティクス インコーポレイテッド | 遺伝子操作された細胞における阻害相互作用を調節するための組成物および方法 |
| EA201891338A1 (ru) * | 2015-12-04 | 2018-12-28 | Новартис Аг | Композиции и способы для иммуноонкологии |
-
2017
- 2017-06-27 SG SG10201705285SA patent/SG10201705285SA/en unknown
-
2018
- 2018-06-27 AU AU2018291556A patent/AU2018291556B2/en not_active Expired - Fee Related
- 2018-06-27 CN CN201880043866.7A patent/CN111630167B/zh active Active
- 2018-06-27 WO PCT/SG2018/050313 patent/WO2019004939A1/en not_active Ceased
- 2018-06-27 US US16/626,395 patent/US12188016B2/en active Active
- 2018-06-27 JP JP2019572710A patent/JP7284718B2/ja active Active
- 2018-06-27 KR KR1020207000349A patent/KR20200035937A/ko not_active Withdrawn
- 2018-06-27 CA CA3066035A patent/CA3066035A1/en not_active Abandoned
- 2018-06-27 SG SG11201911704UA patent/SG11201911704UA/en unknown
- 2018-06-27 EP EP18823314.2A patent/EP3645724A4/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020530981A5 (https=) | ||
| JP7174384B2 (ja) | キメラ２重鎖核酸 | |
| US11260134B2 (en) | Double-stranded nucleic acid complex having overhang | |
| ES2562658T3 (es) | Procedimientos y medios para el salto eficiente del exón 45 en el pre-ARNm de la distrofia muscular de Duchenne | |
| US10538763B2 (en) | Compounds and methods for modulation of DUX4 | |
| EP2961841B1 (en) | Chimeric single-stranded antisense polynucleotides and double-stranded antisense agent | |
| US11433089B2 (en) | Blood-brain barrier permeable heteroduplex nucleic acid | |
| CA3172168A1 (en) | Synthesis of modified oligonucleotides with increased stability | |
| JP2023158214A (ja) | Ｈｉｆ２αの遺伝子発現を阻害する組成物及び方法 | |
| IL262199A (en) | Oligonucleotides for the treatment of eye disease | |
| CN115397436B (zh) | 用于抑制PNPLA3表达的RNAi剂、其药物组合物和使用方法 | |
| WO2016149020A1 (en) | Rna interference agents | |
| JP2018519831A5 (https=) | ||
| KR20180104692A (ko) | Angpt2 및 pdgfb를 표적화하는 rna 복합체를 사용하는 혈관신생 관련 질환의 치료 | |
| WO2016149659A2 (en) | Antisense-induced exon exclusion in myostatin | |
| WO2016149323A1 (en) | Immunomodulatory spherical nucleic acids | |
| US20250388901A1 (en) | Advanced rna targeting (arnatar) | |
| EP3532617A1 (en) | Antisense oligonucleotides | |
| WO2021070959A1 (ja) | 修飾ヘテロ核酸 | |
| US20220162599A1 (en) | Methods and compositions for modulating splicing of alternative introns | |
| US20150329857A1 (en) | Rna interference to activate stem cells | |
| CN112654706B (zh) | 靶向淋巴细胞活化基因3(lag-3)的核酸适体及其用途 | |
| Eritja et al. | Challenges and opportunities for oligonucleotide-based therapeutics by antisense and RNA interference mechanisms | |
| CN121889505A (zh) | 抑制actriib表达的寡核苷酸分子及其用途 | |
| EP4720299A1 (en) | Tgfb2-irf5 therapeutics for cancer |